Erica Shrewsbury, NP
Family · Beckley, WVNPI 1982026712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 912 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 912 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$3K
- AbbVie$2K
- Novo Nordisk$2K
- Amgen$1K
- Novartis$784
- plus $8K from 44 others
What the payments were for
- Food & beverage$19,45798%
- Education$3722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$257
- AIRSUPRA$124
- Wegovy$119
- GENERAL ANGIOPLASTY$118
- Epclusa$112
- PURAPLY WOUND MATRIX$107
- Apligraf$104
- BREZTRI$104
- QULIPTA$103
How this compares
$19,829 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $148,948 |
| JardianceEmpagliflozin | 62 | $74,656 |
| EliquisApixaban | 49 | $66,256 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $48,300 |
| MounjaroTirzepatide | 42 | $46,943 |
| FarxigaDapagliflozin Propanediol | 37 | $40,248 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $32,812 |
| XareltoRivaroxaban | 21 | $31,534 |
| EntrestoSacubitril/Valsartan | 21 | $22,286 |
| Repatha SureclickEvolocumab | 18 | $21,462 |
| LinzessLinaclotide | 30 | $19,770 |
| VascepaIcosapent Ethyl | 37 | $17,753 |
| TrulancePlecanatide | 14 | $13,914 |
| SantylCollagenase Clostridium Hist. | 31 | $13,372 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $12,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,560 | $148,948116 claims |
| Boehringer IngelheimJardiance | $246 | $74,65662 claims |
| PfizerEliquis | $166 | $66,25649 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $2,895 | $56,08473 claims |
| Lilly USA, LLCMounjaro | $717 | $46,94342 claims |
| GSKTrelegy Ellipta | $258 | $32,81238 claims |
| Johnson & JohnsonXarelto | $3,339 | $31,53421 claims |
| AbbVieLinzess, Synthroid | $1,697 | $22,69858 claims |
| NovartisEntresto | $784 | $22,28621 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $714 | $13,91414 claims |
| Smith+NephewSantyl | $256 | $13,37231 claims |
| MerckJanuvia | $294 | $7,15813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Beckley
- Melissa RamseyBeckley$12K
- Jeanine RobinsonBeckley$10K
- Dana FrobleBeckley$10K
- Rosalind BerryBeckley$9K
- Leslie LillyBeckley$8K
- Jennifer WhaleyBeckley$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.